2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH ANDREA APOLO
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook

VIEW ALL BLADDER CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH TOM KEANE
A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JEREMIE CALAIS
Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

VIEW ALL IMAGING VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH FRED SAAD
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment

VIEW ALL nmCRPC VIDEOS

Featured Videos

Discontinuation from Collagenase Clostridium histolyticum Therapy for Peyronie's Disease: Review and Single-Center Cohort Analysis.

Intralesional injection therapy with collagenase Clostridium histolyticum (CCh) is an effective treatment option for Peyronie's disease (PD), but it carries risks, costs, and the need for multiple visits, which may cause patients to discontinue therapy prematurely.

To identify and summarize the current literature on CCh discontinuation and present our experience with CCh discontinuation.

We performed a PubMed review of existing literature on discontinuation from CCh therapy and retrospectively analyzed our prospectively maintained Institutional Review Board-approved CCh database for January 2016-December 2018. Demographic information, clinical outcomes, and communication logs were collected. Reasons for discontinuation of therapy were assessed. A logistic regression to identify factors influencing dropout was performed.

Documentation of discontinuation statistics in published literature, and rates of and reasons for discontinuation in a single-institution cohort.

Our literature review identified 15 studies with specified cohort sizes. Of these, 10 specifically quantified discontinuation rates, which ranged from 13% to 56%. Combined, these studies show a 20% dropout rate. Dissatisfaction with therapy was the most common reason for dropout. In our cohort, 100 men completed a course of 8 CCh injections. Twelve men (10.7%) discontinued therapy, including 4 due to relocation, 3 due to cost, 1 due to a hematoma, 1 due to early satisfaction, 2 due to no perceived improvement, and 1 due to a demanding work schedule. Hematoma formation was a predictor of dropout in our cohort (odds ratio 8.74; P = .037).

Additional focus must be placed on quantifying and evaluating CCh discontinuation. Our findings show that a majority of men complete a full course of 8 injections; most of the few men who dropped out of therapy did so due to relocation. Counseling to reduce CCh discontinuation should focus on initial sexual function, adverse events, and expectations.

Sexual medicine reviews. 2019 Jun 10 [Epub ahead of print]

Arash Amighi, Sriram V Eleswarapu, Neil Mendhiratta, Justin J Nork, Jesse N Mills

Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA., Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: .

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe